What is Citigroup's price target for HCAT?

Citigroup's latest stated price target for Health Catalyst Inc (HCAT) is $55, from its action on Dec 20, 2021.

What is Citigroup's rating on HCAT?

Citigroup rates HCAT Neutral, a neutral rating, as of Aug 11, 2025.

When did Citigroup last change its view on HCAT?

On Aug 11, 2025, Citigroup downgrades to Neutral from Buy.

Citigroup HCAT price target and rating history

Citigroup rates Health Catalyst Inc (HCAT) Neutral with a $55 price target, as of its latest action on Aug 11, 2025. It has published 3 rating actions on HCAT since August 2021, including 0 upgrades and 1 downgrade.

Current rating: Neutral
Price target: $55
Median target, all firms: Too few
Actions on HCAT: 3

Citigroup price target on HCAT

Citigroup price target on HCAT, each point a stated target, August 2021 to December 2021.

Every Citigroup rating on HCAT

Aug 11, 2025
DowngradeCitigroup downgrades to Neutral from Buy
Dec 20, 2021
ReiterateCitigroup cuts its price target to $55 from $68, keeps Buy
Aug 9, 2021
ReiterateCitigroup raises its price target to $68 from $62, keeps Buy

How other firms rate HCAT

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Canaccord Genuity	Hold	$1.80	Aug 21, 2026
Wells Fargo	Equal Weight	$1	Mar 18, 2026

Questions about Citigroup and HCAT

What is Citigroup's price target for HCAT?: Citigroup's latest stated price target for Health Catalyst Inc (HCAT) is $55, from its action on Dec 20, 2021.
What is Citigroup's rating on HCAT?: Citigroup rates HCAT Neutral, a neutral rating, as of Aug 11, 2025.
When did Citigroup last change its view on HCAT?: On Aug 11, 2025, Citigroup downgrades to Neutral from Buy.

More HCAT rating histories

All Citigroup ratings HCAT news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.